E V Gelfand

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. ncbi request reprint Rimonabant: a selective blocker of the cannabinoid CB1 receptors for the management of obesity, smoking cessation and cardiometabolic risk factors
    Eli V Gelfand
    Division of Cardiology Baker 4, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    Expert Opin Investig Drugs 15:307-15. 2006
  2. ncbi request reprint Images in cardiovascular medicine. Sinus of Valsalva aneurysm with right ventricular outflow tract obstruction: evaluation with Doppler, real-time 3-dimensional and contrast echocardiography
    Eli V Gelfand
    Cardiovascular Division, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02215, USA
    Circulation 115:e16-7. 2007
  3. ncbi request reprint Myocardial infarction: contemporary management strategies
    E V Gelfand
    Cardiovascular Division, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    J Intern Med 262:59-77. 2007
  4. ncbi request reprint Predictors of preserved left ventricular systolic function after surgery for chronic organic mitral regurgitation: a prospective study
    Eli V Gelfand
    Department of Medicine Cardiovascular Division, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    J Heart Valve Dis 19:43-50. 2010
  5. ncbi request reprint Rimonabant: a cannabinoid receptor type 1 blocker for management of multiple cardiometabolic risk factors
    Eli V Gelfand
    Cardiovascular Division, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
    J Am Coll Cardiol 47:1919-26. 2006
  6. ncbi request reprint Cardiovascular magnetic resonance imaging for valvular heart disease
    Angela Morello
    Cardiovascular Division, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    Curr Heart Fail Rep 6:160-6. 2009
  7. ncbi request reprint Rimonabant: the role of endocannabinoid type 1 receptor antagonism in modulating the weight and lipid profile of obese patients
    Christopher T Dibble
    Beth Israel Deaconess Medical Center, Boston, MA, USA
    Curr Atheroscler Rep 9:359-66. 2007
  8. ncbi request reprint Severity of mitral and aortic regurgitation as assessed by cardiovascular magnetic resonance: optimizing correlation with Doppler echocardiography
    Eli V Gelfand
    Department of Medicine Cardiovascular Division, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    J Cardiovasc Magn Reson 8:503-7. 2006
  9. ncbi request reprint Antibiotics for secondary prevention of coronary artery disease: an ACES hypothesis but we need to PROVE IT
    Eli V Gelfand
    Cardiovascular Division, Beth Israel Deaconess Medical Center, Boston, Mass, USA
    Am Heart J 147:202-9. 2004

Detail Information

Publications9

  1. ncbi request reprint Rimonabant: a selective blocker of the cannabinoid CB1 receptors for the management of obesity, smoking cessation and cardiometabolic risk factors
    Eli V Gelfand
    Division of Cardiology Baker 4, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    Expert Opin Investig Drugs 15:307-15. 2006
    ..As an agent with a novel mechanism of action, rimonabant has the potential to be a useful adjunct to lifestyle modification in the treatment of obesity, metabolic syndrome and cigarette smoking...
  2. ncbi request reprint Images in cardiovascular medicine. Sinus of Valsalva aneurysm with right ventricular outflow tract obstruction: evaluation with Doppler, real-time 3-dimensional and contrast echocardiography
    Eli V Gelfand
    Cardiovascular Division, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02215, USA
    Circulation 115:e16-7. 2007
  3. ncbi request reprint Myocardial infarction: contemporary management strategies
    E V Gelfand
    Cardiovascular Division, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    J Intern Med 262:59-77. 2007
    ..Finally, evidence-based approach to secondary prevention is outlined...
  4. ncbi request reprint Predictors of preserved left ventricular systolic function after surgery for chronic organic mitral regurgitation: a prospective study
    Eli V Gelfand
    Department of Medicine Cardiovascular Division, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    J Heart Valve Dis 19:43-50. 2010
    ..A quantitative volumetric cardiovascular magnetic resonance (CMR) system was used prospectively to study these relationships, and to define predictors of postoperative LV systolic function after surgery for chronic severe MR...
  5. ncbi request reprint Rimonabant: a cannabinoid receptor type 1 blocker for management of multiple cardiometabolic risk factors
    Eli V Gelfand
    Cardiovascular Division, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
    J Am Coll Cardiol 47:1919-26. 2006
    ..As an agent with a novel mechanism of action, rimonabant has a potential to be a useful adjunct to lifestyle and behavior modification in treatment of multiple cardiometabolic risk factors, including abdominal obesity and smoking...
  6. ncbi request reprint Cardiovascular magnetic resonance imaging for valvular heart disease
    Angela Morello
    Cardiovascular Division, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    Curr Heart Fail Rep 6:160-6. 2009
    ..This article reviews the clinical applications of CMR in assessment of VHD...
  7. ncbi request reprint Rimonabant: the role of endocannabinoid type 1 receptor antagonism in modulating the weight and lipid profile of obese patients
    Christopher T Dibble
    Beth Israel Deaconess Medical Center, Boston, MA, USA
    Curr Atheroscler Rep 9:359-66. 2007
    ..Rimonabant is a novel agent that has the potential to be a useful adjunct to lifestyle and behavior modification in treatment of abdominal obesity, dyslipidemia, and dysglycemia...
  8. ncbi request reprint Severity of mitral and aortic regurgitation as assessed by cardiovascular magnetic resonance: optimizing correlation with Doppler echocardiography
    Eli V Gelfand
    Department of Medicine Cardiovascular Division, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    J Cardiovasc Magn Reson 8:503-7. 2006
    ..Therefore, we sought to define the CMR regurgitant fractions that best correlate with qualitative mild, moderate, and severe regurgitation by color Doppler echocardiography...
  9. ncbi request reprint Antibiotics for secondary prevention of coronary artery disease: an ACES hypothesis but we need to PROVE IT
    Eli V Gelfand
    Cardiovascular Division, Beth Israel Deaconess Medical Center, Boston, Mass, USA
    Am Heart J 147:202-9. 2004